ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis

NASDAQ:ZYBT • KYG989MS1016

0.92 USD
-0.04 (-4.37%)
At close: Feb 17, 2026
1 USD
+0.08 (+8.7%)
After Hours: 2/10/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZYBT. ZYBT was compared to 191 industry peers in the Pharmaceuticals industry. ZYBT may be in some trouble as it scores bad on both profitability and health. ZYBT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ZYBT had negative earnings in the past year.
  • ZYBT had a positive operating cash flow in the past year.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -2.05%, ZYBT is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
  • ZYBT has a better Return On Equity (-3.46%) than 77.49% of its industry peers.
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROIC N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 5 10 15

1.3 Margins

  • ZYBT's Profit Margin has declined in the last couple of years.
  • ZYBT's Operating Margin has declined in the last couple of years.
  • ZYBT's Gross Margin of 44.51% is fine compared to the rest of the industry. ZYBT outperforms 63.87% of its industry peers.
  • In the last couple of years the Gross Margin of ZYBT has declined.
  • ZYBT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.51%
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ZYBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ZYBT has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ZYBT has an improved debt to assets ratio.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of 1.61, we must say that ZYBT is in the distress zone and has some risk of bankruptcy.
  • ZYBT's Altman-Z score of 1.61 is fine compared to the rest of the industry. ZYBT outperforms 60.21% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that ZYBT is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.02, ZYBT perfoms like the industry average, outperforming 54.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.61
ROIC/WACCN/A
WACC7.51%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 1.49 indicates that ZYBT should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.49, ZYBT is doing worse than 71.73% of the companies in the same industry.
  • A Quick Ratio of 1.10 indicates that ZYBT should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.10, ZYBT is not doing good in the industry: 76.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.1
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • ZYBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -123.72%.
  • Measured over the past years, ZYBT shows a very strong growth in Earnings Per Share. The EPS has been growing by 528.02% on average per year.
  • The Revenue for ZYBT has decreased by -18.89% in the past year. This is quite bad
  • The Revenue has been growing by 854.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ZYBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ZYBT is valued a bit cheaper than the industry average as 79.58% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 26.56
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ZYBT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (2/17/2026, 8:00:03 PM)

After market: 1 +0.08 (+8.7%)

0.92

-0.04 (-4.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.33%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap43.60M
Revenue(TTM)248.68M
Net Income(TTM)-10.36M
AnalystsN/A
Price TargetN/A
Short Float %0.54%
Short Ratio1.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP-1.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF 24.31
P/B 1.01
P/tB 1.09
EV/EBITDA 26.56
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY4.11%
SpS0.76
BVpS0.91
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.51%
FCFM N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.37
Cap/Depr 50.15%
Cap/Sales 5.07%
Interest Coverage N/A
Cash Conversion 97.56%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.1
Altman-Z 1.61
F-Score3
WACC7.51%
ROIC/WACCN/A
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.24%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A

ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ

What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZYBT.


What is the valuation status of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a valuation rating of 1 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Overvalued.


Can you provide the profitability details for ZHENGYE BIOTECHNOLOGY HOLDIN?

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 2 / 10.


What is the financial health of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 3 / 10.